Erica Marini, PharmD, and guest, Millad Sobhanian, PharmD, BCPS, discuss 3 major Alzheimer disease developments including a newly approved agitation therapy, the delayed FDA decision on lecanemab subcutaneous initiation dosing, and a controversial review on anti-amyloid therapies.
In this debut episode Erica Marini and her colleagues discuss the critical role pharmacists play in complex neurologic care and the latest emerging therapies and research presented at the AAN 2026 Annual Meeting.
This new podcast will explore therapies, trends, and clinical decisions shaping neurology from a pharmacist's point of view.
